Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Coherus Oncology: 3 Key Takeaways for Long-Term Investors

With less than 12 months of cash on hand, the margin for error is thin, and the oncologist survey on LOQTORZI's standard-of-care status may matter as much as any cost cut.

We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at fool.com →

More in Finance & Markets

More from Tuesday 10 November →